Johnson & Johnson effort to resolve talc cancer lawsuits in bankruptcy fails a second time

Johnson & Johnson effort to resolve talc cancer lawsuits in bankruptcy fails a second time


In this photo illustration, a container of Johnson and Johnson baby powder is displayed on April 05, 2023 in San Anselmo, California. 

Justin Sullivan | Getty Images

A federal bankruptcy judge on Friday rejected Johnson & Johnson‘s second attempt to resolve tens of thousands of lawsuits alleging the company’s talc baby powder and other talc-based products caused cancer. 

J&J in 2021 offloaded those talc liabilities into a new subsidiary, LTL Management, and immediately filed for Chapter 11 bankruptcy protections. 

Judge Michael Kaplan in Trenton, New Jersey, said in an opinion that LTL Management’s second bankruptcy must be dismissed because the subsidiary was not in “imminent” or “immediate financial distress.” A U.S. appeals court in April dismissed the first bankruptcy attempt over the same reason. 

The decision jeopardizes J&J’s proposed $8.9 billion settlement that would stop new lawsuits from being filed. The company previously said more than 60,000 claimants have already committed to voting in favor of the plan.

“LTL commenced its bankruptcy case in good faith and in strict compliance with the Bankruptcy Code,” J&J said in a statement. 

“The Bankruptcy Code does not require a business to be engulfed in ‘flames’ to seek a reorganization supported by the vast majority of claimants,” said Erik Haas, J&J’s worldwide vice president of litigation in the statement.

J&J contends that research and clinical evidence demonstrates that its talc products remain safe.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More